CanSino Biologics (Germany) Performance
| CJH Stock | 3.66 0.12 3.17% |
On a scale of 0 to 100, CanSino Biologics holds a performance score of 8. The firm shows a Beta (market volatility) of 0.59, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, CanSino Biologics' returns are expected to increase less than the market. However, during the bear market, the loss of holding CanSino Biologics is expected to be smaller as well. Please check CanSino Biologics' downside variance, rate of daily change, and the relationship between the maximum drawdown and skewness , to make a quick decision on whether CanSino Biologics' price patterns will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in CanSino Biologics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile basic indicators, CanSino Biologics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 4.4 B | |
| Total Cashflows From Investing Activities | -2.6 B |
CanSino |
CanSino Biologics Relative Risk vs. Return Landscape
If you would invest 280.00 in CanSino Biologics on September 27, 2024 and sell it today you would earn a total of 86.00 from holding CanSino Biologics or generate 30.71% return on investment over 90 days. CanSino Biologics is generating 0.5572% of daily returns and assumes 5.2192% volatility on return distribution over the 90 days horizon. Simply put, 46% of stocks are less volatile than CanSino, and 89% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
CanSino Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CanSino Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CanSino Biologics, and traders can use it to determine the average amount a CanSino Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1068
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CJH | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.22 actual daily | 46 54% of assets are more volatile |
Expected Return
| 0.56 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average CanSino Biologics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CanSino Biologics by adding it to a well-diversified portfolio.
CanSino Biologics Fundamentals Growth
CanSino Stock prices reflect investors' perceptions of the future prospects and financial health of CanSino Biologics, and CanSino Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CanSino Stock performance.
| Return On Equity | 0.0111 | |||
| Return On Asset | -0.0207 | |||
| Current Valuation | 3.4 B | |||
| Shares Outstanding | 114.78 M | |||
| Price To Book | 2.25 X | |||
| Price To Sales | 2.17 X | |||
| Revenue | 4.3 B | |||
| EBITDA | 2.05 B | |||
| Total Debt | 40 M | |||
| Book Value Per Share | 29.22 X | |||
| Cash Flow From Operations | 2.05 B | |||
| Earnings Per Share | 0.52 X | |||
| Total Asset | 11.87 B | |||
About CanSino Biologics Performance
Assessing CanSino Biologics' fundamental ratios provides investors with valuable insights into CanSino Biologics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the CanSino Biologics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about CanSino Biologics performance evaluation
Checking the ongoing alerts about CanSino Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CanSino Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CanSino Biologics is way too risky over 90 days horizon | |
| CanSino Biologics appears to be risky and price may revert if volatility continues | |
| About 27.0% of the company shares are held by company insiders |
- Analyzing CanSino Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CanSino Biologics' stock is overvalued or undervalued compared to its peers.
- Examining CanSino Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CanSino Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CanSino Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CanSino Biologics' stock. These opinions can provide insight into CanSino Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for CanSino Stock Analysis
When running CanSino Biologics' price analysis, check to measure CanSino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CanSino Biologics is operating at the current time. Most of CanSino Biologics' value examination focuses on studying past and present price action to predict the probability of CanSino Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CanSino Biologics' price. Additionally, you may evaluate how the addition of CanSino Biologics to your portfolios can decrease your overall portfolio volatility.